Know Cancer

forgot password

A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy

Phase 2
18 Years
Open (Enrolling)
Adenocarcinoma of the Pancreas, Metastatic Disease

Thank you

Trial Information

A Phase II Single Arm Study of AUY922 in Patients With Metastatic Pancreatic Adenocarcinoma Who Are Resistant to First Line Chemotherapy

This is a single arm open label Phase II clinical trial evaluating the efficacy of AUY922 in
patients with advanced pancreatic cancer who have been previously treated with or are
intolerant to first line chemotherapy. The primary objective is to assess the efficacy of
this agent by assessing the disease control rate (DCR) (objective response plus prolonged
stable disease (>16 weeks).

The current standard therapy for patients who have advanced, metastatic or inoperable
pancreatic cancer previously treated with or intolerant to first line chemotherapy is best
supportive care. New treatment options are urgently needed.

Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone protein involved in
the stabilization of a number of membrane and intracellular proteins including HER2,
BCR-ABL, C-SRC, EGFR, RAF, VEGFR, AKT, and RAS. Many of these proteins are highly expressed
in pancreatic adenocarcinoma.

AUY922 is a novel isoxazole-based HSP90 inhibitor. AUY922 acts by inhibiting HSP90 ATPase
activity (IC50 of 30 nm) and preventing the formation of a multichaperone complex between
HSP90 and other heat shock proteins. This then prevents HSP90 from performing its functions
on client proteins.

Inclusion Criteria:

- Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas
with metastatic disease

- Patients have received at least one prior systemic anticancer therapy for their
advanced disease, which may include a gemcitabine based or 5-FU based therapeutic
regimen. Patients with resected disease who relapse within 6 months of completion of
adjuvant gemcitabine would also be eligible.

- Patients with progressive disease (radiological confirmation required) after at least
one line of chemotherapy for pancreatic adenocarcinoma. Patients must have at least
one measurable lesion as defined by RECIST criteria. Irradiated lesions are only
evaluable for disease progression.

- Patient's age is ≥ 18 years of age

- Patients may have received prior radiation treatment for management of local disease
providing that disease progression has been documented, all toxicities have resolved,
to ≤ grade 1 and the last fraction of radiation treatment was completed at least 4
weeks prior to randomization (2 weeks for palliative radiotherapy).

- ECOG performance status of 0 or 1.

- Life expectancy of greater than 12 weeks

- Patients must have following laboratory values within 7 days prior to starting

- Hematological:

- Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L

- Hemoglobin (Hgb) ≥ 90 g/L

- Platelets (plt) ≥ 100 x 109/L

- Biochemistry:

- Potassium within normal limits

- Total calcium (corrected for serum albumin) and Phosphorus within normal limits

- Magnesium above LLN or correctable with supplements

- Adequate liver function defined as:

- AST/SGOT and ALT/SGPT ≤ 1.5 x Upper Limit of Normal (ULN)

- AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) if liver metastases
are present

- Serum bilirubin ≤ 1.5 x ULN

- eGFR ≥ 50 mL /min

- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
(minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to
randomization. Postmenopausal women must have been amenorrheic for ≥ 24 months in
order to be considered "of non-childbearing potential". This should be documented
appropriately in the patient's medical history.

Exclusion Criteria:

- Patients with a history of another primary malignancy that is clinically significant
or requires active intervention

- Prior treatment with any HSP90 or HDAC inhibitor compounds, including valproic acid

- Patients with a significant history of cardiac disease, including:

- Impaired cardiac function, including any one of the following:

- History (or family history) of long QT syndrome

- Mean QTc ≥ 450 msec on baseline ECG

- History of clinically manifested ischemic heart disease ≤ 6 months prior to
study start

- History of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by

- Clinically significant ECG abnormalities

- History or presence of atrial fibrillation, atrial flutter or ventricular
arrhythmias including ventricular tachycardia or Torsades de Pointes

- Other clinically significant heart disease (e.g. congestive heart failure,
uncontrolled hypertension, history of labile hypertension, or history of poor
compliance with an antihypertensive regimen)

- Clinically significant resting bradycardia (< 50 beats per minute)

- Patients who are currently receiving treatment with any medication which has a
relative risk of prolonging the QTc interval or inducing Torsades de Pointes and
cannot be switched to an alternative drug or discontinued prior to commencing
start of treatment.

- Obligate use of a cardiac pacemaker

- Patients with a serious active infection at the time of registration or other serious
underlying medical conditions that would impair the ability of the patient to receive
protocol treatment.

- Patients with a known central nervous system metastases. CT scan of the brain is NOT
required unless there is suspicion of CNS metastases.

- Patients with any condition (e.g. psychological, geographical, etc.) that does not
permit compliance with the protocol.

- Pregnant or lactating females.

- Women of child bearing potential or sexually active males who are not employing
adequate contraception. Adequate methods of contraception include use of oral
contraceptives or Depot-Provera, with an additional barrier method (diaphragm with
spermicidal gel OR condoms with spermicide); a double-barrier method (diaphragm with
spermicidal gel AND condoms with spermicide); partner vasectomy and total abstinence.

- Patients who received systemic anti-cancer treatment prior to the first dose of study
medication within the following time frames:

- Radiotherapy, conventional chemotherapy: within 4 weeks

- Palliative radiotherapy: within 2 weeks

- Monoclonal antibodies: within 4 weeks

- Nitrosoureas and mitomycin: within 6 weeks

- Targeted agents or investigational dugs: within 4 weeks

- Patients who have had any surgery within 2 weeks prior to registration or who have
not recovered from such therapy.

- Patients known to be HIV positive. Testing is not required in the absence of
clinical signs and symptoms suggestive of HIV infection.

- Treatment with therapeutic doses of coumarin-type anticoagulants. (Maximum daily dose
of 2 mg, for line patency permitted)

- Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g.
Gilbert's syndrome)

- Unresolved diarrhea ≥ CTCAE grade 2 within 72 hours prior to registration

- Patients with acute or chronic renal disease. Chronic renal disease will be defined
as patients who have stable creatinine ≥ to 1.5 ULN and/or eGFR ≤ 50mL/min. Acute
renal disease will be defined as patients that have an acute (within less then 4
weeks) rise in creatinine to ≥ 1.5 ULN and/or eGFR ≤ 50mL/min, that has not resolved
to the previously normal baseline levels.

- Patients with active liver disease that requires intervention.

- Patients who cannot give informed consent (i.e. mentally incompetent patients, or
those physically incapacitated such as comatose patients). Patients competent but
physically unable to sign the consent form may have the document signed by their
nearest relative or legal guardian. Each patient will be provided with a full
explanation of the study before consent is requested.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Determine anti-tumor activity using disease control rate

Outcome Description:

Disease control rate is defined as objective response rate plus prolonged stable disease (≥16 weeks).

Outcome Time Frame:

18-20 months

Safety Issue:


Principal Investigator

Malcolm J. Moore, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Princess Margaret Hospital, Canada


Canada: Health Canada

Study ID:




Start Date:

January 2012

Completion Date:

August 2013

Related Keywords:

  • Adenocarcinoma of the Pancreas
  • Metastatic Disease
  • AUY922
  • Pancreas
  • Pancreatic cancer
  • Adenocarcinoma of the pancreas
  • Cancer of the pancreas
  • Metastatic
  • Advanced
  • Advanced disease
  • Prior systemic anticancer therapy
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Neoplasm Metastasis
  • Pancreatic Neoplasms